Jason Throne - Dec 15, 2023 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role
Chief Legal Officer
Signature
/s/ Jason Throne
Stock symbol
IDYA
Transactions as of
Dec 15, 2023
Transactions value $
-$146,871
Form type
4
Date filed
12/19/2023, 05:37 PM
Previous filing
Nov 7, 2023
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Options Exercise $133K +10K $13.34 10K Dec 15, 2023 Direct
transaction IDYA Common Stock Sale -$350K -10K -100% $35.04 0 Dec 15, 2023 Direct F1, F2
transaction IDYA Common Stock Options Exercise $70.1K +10K $7.01* 10K Dec 18, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDYA Stock Option (Right to Buy) Options Exercise $0 -10K -17.36% $0.00 47.6K Dec 15, 2023 Common Stock 10K $13.34 Direct F3
transaction IDYA Stock Option (Right to Buy) Options Exercise $0 -10K -17.12% $0.00 48.4K Dec 18, 2023 Common Stock 10K $7.01 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 29, 2023.
F2 This transaction was executed in multiple trades in prices ranging from $35.00 to $35.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 25% of the shares subject to the option vest on the first anniversary measured from July 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F4 The shares subject to the option are fully vested and exercisable.